Niu Y R, Wu H W, Liang Z Y
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China.
Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):435-440. doi: 10.3760/cma.j.cn112151-20191224-00825.
To study the clinicopathologic characteristics and relevant factors affecting prognosis of patients with synchronous bilateral breast cancer. The clinical data, pathologic characteristics and immunohistochemical expression characteristics of 151 patients with synchronous bilateral breast cancers diagnosed in Peking Union Medical College Hospital from 2008 to 2018 were collected and analyzed. The factors affecting the prognosis were analyzed by Log rank test, Kaplan-Meier survival analysis, Cox regression and other methods. Synchronous bilateral breast cancer cases accounted for 1.2% (151/12 239) of all breast cancer patients in the same period, and 14.6% (22/151) had a family history. The patients' age range was 22-88 years, mainly female, with a mean survival of 42.5 months. There were 106 patients with synchronous bilateral invasive breast cancers, 6 patients with synchronous bilateral breast cancer in situ, and 39 patients with unilateral invasive breast cancer and unilateral breast cancer in situ. In synchronous bilateral invasive breast cancers, the histological type was mainly non-specific type (84.9%, 180/212), the histological grade was mainly Grade 2 (60.8%,129/212), the TNM stage was mainly stage Ⅰ (50.5%, 107/212), the tumor size was mainly T1 (68.9%, 146/212), and the regional lymph node was mainly N0 (61.8%, 131/212). The molecular subtypes were mainly Luminal A-like (38.1%, 75/197) and Luminal B-like (43.7%, 86/197); ER (78.2%, 154/197) and PR (72.1%,142/197)were mainly positive, and HER2 was mainly negative (91.9%, 181/197). There were 85 (80.2%) patients and 75 (70.8%) patients with the same histological type and histological grade on both sides, respectively. The concordance of tumor size T stage and the regional lymph nodes N stage were 58.5% (62/106) and 55.7% (59/106), respectively. The concordance of molecular subtype was 54.9% (50/91), and the concordance of ER, PR, HER2 and Ki-67 were 83.5% (76/91), 76.9% (70/91), 89.0% (81/91) and 59.3% (54/91), respectively. The expression of ER and PR in synchronous bilateral invasive breast cancer was significantly correlated with prognosis (0.05). Among patients with synchronous bilateral breast cancers, bilateral invasive breast cancer is the most common, the prognosis is the worst, and the pathologic characteristics of bilateral breast cancer tend to be consistent. The expression of ER and PR in synchronous bilateral invasive breast cancer is significantly correlated with prognosis, that is, best for bilateral ER-positive patients, worst for bilateral ER-negative patients, and intermediate for unilateral ER-positive patients, thus suggesting the importance of ER and PR detection in synchronous bilateral invasive breast cancers.
研究同期双侧乳腺癌患者的临床病理特征及影响预后的相关因素。收集并分析2008年至2018年在北京协和医院确诊的151例同期双侧乳腺癌患者的临床资料、病理特征及免疫组化表达特征。采用Log rank检验、Kaplan-Meier生存分析、Cox回归等方法分析影响预后的因素。同期双侧乳腺癌病例占同期所有乳腺癌患者的1.2%(151/12 239),14.6%(22/151)有家族史。患者年龄范围为22 - 88岁,以女性为主,平均生存期为42.5个月。同期双侧浸润性乳腺癌患者106例,同期双侧原位乳腺癌患者6例,单侧浸润性乳腺癌合并单侧原位乳腺癌患者39例。在同期双侧浸润性乳腺癌中,组织学类型主要为非特殊类型(84.9%,180/212),组织学分级主要为2级(60.8%,129/212),TNM分期主要为Ⅰ期(50.5%,107/212),肿瘤大小主要为T1(68.9%,146/212),区域淋巴结主要为N0(61.8%,131/212)。分子亚型主要为Luminal A样(38.1%,75/197)和Luminal B样(43.7%,86/197);ER(78.2%,154/197)和PR(72.1%,142/197)主要为阳性,HER2主要为阴性(91.9%,181/197)。双侧组织学类型相同和组织学分级相同的患者分别有85例(80.2%)和75例(70.8%)。肿瘤大小T分期和区域淋巴结N分期的一致性分别为58.5%(62/106)和55.7%(59/106)。分子亚型的一致性为54.9%(50/91),ER、PR、HER2和Ki-67的一致性分别为83.5%(76/91)、76.9%(70/91)、89.0%(81/91)和59.3%(54/91)。同期双侧浸润性乳腺癌中ER和PR的表达与预后显著相关(P<0.05)。在同期双侧乳腺癌患者中,双侧浸润性乳腺癌最常见,预后最差,双侧乳腺癌的病理特征趋于一致。同期双侧浸润性乳腺癌中ER和PR的表达与预后显著相关,即双侧ER阳性患者预后最好,双侧ER阴性患者预后最差,单侧ER阳性患者预后居中,从而提示ER和PR检测在同期双侧浸润性乳腺癌中的重要性。